
    
      Participants will receive either MK-2118 monotherapy or MK-2118 in combination with
      pembrolizumab for up to 35 cycles for Arms 1-3 or up to 36 cycles for Arm 4 (approximately 2
      years).

      All participants will undergo at least a 24-hour observation period following the first three
      administrations of MK-2118 (Arms 1-3: Cycle 1 Days 1, 8, and 15. Arm 4: Cycle 1 Days 1 and 8;
      and Cycle 2 Day 1).
    
  